Monopar Therapeutics (NASDAQ:MNPR) Given “Buy” Rating at Chardan Capital

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $100.00 price objective on the stock. Chardan Capital’s price target would suggest a potential upside of 48.30% from the company’s current price.

MNPR has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Thursday, January 22nd. Barclays set a $125.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a report on Monday, October 13th. BTIG Research reaffirmed a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, January 14th. Raymond James Financial lowered shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their target price for the company from $142.00 to $123.00 in a report on Friday, November 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $67.43 on Thursday. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The firm’s 50 day moving average price is $72.87 and its 200-day moving average price is $65.31. The stock has a market cap of $450.43 million, a P/E ratio of -19.60 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). As a group, equities analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling at Monopar Therapeutics

In related news, CFO Quan Anh Vu bought 1,500 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were purchased at an average price of $69.95 per share, with a total value of $104,925.00. Following the transaction, the chief financial officer owned 1,500 shares in the company, valued at $104,925. This trade represents a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MNPR. Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics during the first quarter valued at $673,000. Jane Street Group LLC purchased a new position in shares of Monopar Therapeutics during the 1st quarter worth about $377,000. AlphaQuest LLC grew its holdings in Monopar Therapeutics by 46.8% during the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after purchasing an additional 569 shares during the last quarter. Geode Capital Management LLC grew its holdings in Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after purchasing an additional 48,379 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics in the 2nd quarter worth about $34,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.